NKTR * Stock Overview A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Nektar Therapeutics Competitors Price History & Performance
Summary of share price highs, lows and changes for Nektar Therapeutics Historical stock prices Current Share Price US$18.00 52 Week High US$18.00 52 Week Low US$18.00 Beta 0.56 1 Month Change n/a 3 Month Change n/a 1 Year Change n/a 3 Year Change -94.20% 5 Year Change n/a Change since IPO -97.25%
Recent News & Updates
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Dec 08
Ampersand Management LLC completed the acquisition of Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR). Dec 03
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 06 Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 05
See more updates
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Dec 08
Ampersand Management LLC completed the acquisition of Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR). Dec 03
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 06 Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 05
Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases Oct 29
Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia Oct 17
Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024 May 03
Nektar Therapeutics, Annual General Meeting, Jun 05, 2024 Apr 28 Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC Mar 20
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Mar 05 Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC Mar 04
Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024 Feb 27
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 29
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 28
Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy Oct 14
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer Sep 28
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis Sep 14
Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company Aug 08
Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index Jun 25
Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule Jun 03
Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023 May 10
Insufficient new directors Jan 01
Insider recently sold Mex$928k worth of stock Nov 19
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy Nov 10
Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 3Q 2021) Nov 05
Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC). Oct 08
Insider recently sold Mex$267k worth of stock Sep 28
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress Sep 07
CEO, President & Director recently sold Mex$1.3m worth of stock Aug 20
Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma Aug 17
Second quarter 2022 earnings released: US$0.85 loss per share (vs US$0.69 loss in 2Q 2021) Aug 05
Nektar Therapeutics Provides Earnings Guidance for the Year 2022 Aug 05
Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022 Jul 28 Nektar Promotes Jillian B. Thomsen to Senior Vice President
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index Jun 26 Shareholder Returns NKTR * MX Pharmaceuticals MX Market 7D n/a -3.4% -2.9% 1Y n/a -27.4% -14.0%
See full shareholder returns
Return vs Market: Insufficient data to determine how NKTR * performed against the MX Market .
Price Volatility Is NKTR *'s price volatile compared to industry and market? NKTR * volatility NKTR * Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.0% 10% least volatile stocks in MX Market 2.6%
Stable Share Price: NKTR *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine NKTR *'s volatility change over the past year.
About the Company Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. The company serves its clients in the United States and internationally.
Show more Nektar Therapeutics Fundamentals Summary How do Nektar Therapeutics's earnings and revenue compare to its market cap? NKTR * fundamental statistics Market cap Mex$3.44b Earnings (TTM ) -Mex$3.38b Revenue (TTM ) Mex$1.87b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NKTR * income statement (TTM ) Revenue US$93.14m Cost of Revenue US$29.99m Gross Profit US$63.15m Other Expenses US$231.45m Earnings -US$168.30m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.91 Gross Margin 67.80% Net Profit Margin -180.70% Debt/Equity Ratio 200.1%
How did NKTR * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 11:52 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nektar Therapeutics is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Difei Yang Aegis Capital Corporation Richard Silver Barclays Aydin Huseynov Benchmark Company
Show 31 more analysts 